SCHEMBL10215325

SCHEMBL10215325

O=C(NCc1ccc(Cl)s1)c1cc(O)c2cc(-c3ccoc3)cc(C(F)(F)F)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 3/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.37
▸ ERN1 O75460 1/20 0.37
▸ HSD17B13 Q7Z5P4 2/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ PRSS12 P56730 2/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ KLKB1 P03952 2/20 0.31
▸ HPGD P15428 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ F2 P00734 1/20 0.31
▸ MAPK8 P45983 1/20 0.31
▸ MAPK9 P45984 1/20 0.31
▸ MAPK10 P53779 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ PPARG P37231 1/20 0.31
▸ PPARD Q03181 1/20 0.31
▸ PPARA Q07869 1/20 0.31
▸ RHOC P08134 1/20 0.30
▸ RHOA P61586 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10215309 0.85 RAB9A (0.43) HIF1AMAOB
SCHEMBL10215314 0.85 SCD (0.42) SCDNPSR1
SCHEMBL10215323 0.84 SCD (0.41) SCDNPSR1HSD17B13PTGS2PRSS12
SCHEMBL10216308 0.83 SCD (0.42) SCDNPSR1HSD17B13PTGS2PRSS12
SCHEMBL10215288 0.79 RAB9A (0.42) HSD17B13HIF1AHPGDTSHR
SCHEMBL10215308 0.78 ERN1 (0.47) ERN1
SCHEMBL12066784 0.77 SCD (0.37) SCDNPSR1HSD17B13PRSS12HPGD
SCHEMBL10215326 0.77 RAB9A (0.42) NPSR1HIF1AHPGD
SCHEMBL10215331 0.76 NPC1 (0.43) NPSR1HIF1AHPGD
SCHEMBL10215329 0.74 HSD17B10 (0.47) NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053148-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD SCIENCES, INC. (US) 2012-03-01 — — US disclosed
US-20120053148-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD SCIENCES, INC. (US) 2012-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053148-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, FABP1, EIF2AK2 SCD 2390/4885NPSR1 4378/4885ERN1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback